Regeneron Pharmaceuticals Inc. buy Zacks Research
Start price
10.01.26
/
50%
€683.00
Target price
10.01.27
-
Performance (%)
-7.17%
Price
22:25
€633.10
Summary
This prediction is currently active. With a performance of -7.17%, the BUY prediction for Regeneron Pharmaceuticals Inc. by Zacks_Research is down slightly. Dividends of €0.94 are taken into consideration when calculating the performance. This prediction currently runs until 10.01.27. The prediction end date can be changed by Zacks_Research at any time. Zacks_Research has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Regeneron Pharmaceuticals Inc. | -3.853% | -3.853% |
| iShares Core DAX® | 0.444% | 3.030% |
| iShares Nasdaq 100 | 3.819% | 4.073% |
| iShares Nikkei 225® | 1.148% | 6.904% |
| iShares S&P 500 | 2.371% | 2.677% |
Comments by Zacks_Research for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Ratings data for REGN provided by MarketBeat